CHŪŌ-KU | Jotup

Ubie's new Generative AI feature for doctors effortlessly summarizes patient findings and streamlines medical record documentation with a 90% User Satisfaction rate.

Retrieved on:

Tuesday, October 17, 2023

Patient, EHR, Communication, LLM, Nursing, Health insurance

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie , Inc. (Headquartered in Chuo-ku, Tokyo, Co-Representative Directors: Yoshinori Abe & Kota Kubo, referred to as 'Ubie') released a new feature utilizing generative AI (LLM: Large Language Model) for doctors to generate AI-based summarizes from patient visits.

Key Points:

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie , Inc. (Headquartered in Chuo-ku, Tokyo, Co-Representative Directors: Yoshinori Abe & Kota Kubo, referred to as 'Ubie') released a new feature utilizing generative AI (LLM: Large Language Model) for doctors to generate AI-based summarizes from patient visits.
This feature uses the LLM to summarize patients' symptoms and free-response answers in the 'Ubie Medical Navi,' product.
It was developed based on the needs of doctors who want to spend more time on face-to-face communication.
Allowing doctors to grasp the patient's condition quickly and spend less time on preparing notes for EHR systems.

Embedded Flash Memory Developer Floadia Raises 1.05 Billion Yen from Inabata and Others

Retrieved on:

Wednesday, October 11, 2023

Inabata & Co., Ltd., UMC, Faraday Technology, AI, Japan Finance Corporation, Intellectual property, TSMC, Electronics, Temperature, G1, CIM, INCJ, Venture round, Computer data storage, Memory

TOKYO, Oct. 11, 2023 /PRNewswire/ -- Floadia Corporation (hereinafter referred to as "Floadia"), which develops embedded flash memory IP cores based in the Tokyo suburb of Kodaira-shi, has raised approximately 1.05 billion yen in Series D round.

Key Points:

TOKYO, Oct. 11, 2023 /PRNewswire/ -- Floadia Corporation (hereinafter referred to as "Floadia"), which develops embedded flash memory IP cores based in the Tokyo suburb of Kodaira-shi, has raised approximately 1.05 billion yen in Series D round.
Floadia will use the funds raised to strengthen sales activities promoting its current primary business, embedded flash memory IP cores, to semiconductor manufacturers, and to enhance developing ultra-low power consumption AI accelerator chips that utilize flash memory devices.
Floadia is developing Computing in Memory (CIM) chips, which use flash memory devices as information transmission media, as a pillar of the next business following flash memory IP cores.
Floadia's flash memory solves these issues with analog memory technology and enables advanced AI inference calculations in edge environments with significantly low power consumption.

ZENI is Listed on BitMart

Retrieved on:

Friday, October 14, 2022

Sale, Sepia, 3D, Katana, GLOBE, Cryptocurrency, Furniture, Metaverse

Edoverse's native token "Zeni" is issued by the Edoverse Foundation (Headquarters: Panama; CEO: Julia Martinez), which is creating "play-to-earn" GameFi, is to be listed on the American cryptocurrency exchange "BitMart".

Key Points:

Edoverse's native token "Zeni" is issued by the Edoverse Foundation (Headquarters: Panama; CEO: Julia Martinez), which is creating "play-to-earn" GameFi, is to be listed on the American cryptocurrency exchange "BitMart".
Zeni is a token that is circulating in Edoverse developed by Edoverse Foundation.
Currently, Edoverse Foundation has already announced its sepia paper, Edoland NFT sale, ZENI token and KOBAN token deployments, various 3D teasers, avatar images, Katana NFTs, and more.
As BitMart is not registered in Japan, Japanese residents are not able to trade ZENI on BitMart.

Paramedic Training VR Nearly Doubles Students' Understanding of Teamwork in Medicine.

Retrieved on:

Tuesday, May 31, 2022

TOKYO, May 31, 2022 /PRNewswire/ -- Jolly Good Inc. (based in Chuo-ku, Tokyo, Japan; CEO: Kensuke Joji; hereafter "Jolly Good"), is pleased to announce that the educational effect of VR was confirmed as the result of the demonstration test conducted for 663 students at 14 vocational schools throughout Japan which are registered with Japan EMT School Association (JESA：Chief Chairman, Shuji Tanaka) in the effect verification of VR clinical training curriculum adopted by the Ministry of Education, Culture, Sports, Science and Technology in "Demonstrative Research on the Utilization of Advanced Technology in Vocational Schools in 2021".

Key Points:

As a result, it was confirmed that VR teaching materials improve the effectiveness of learning in-hospital care by paramedics under the revised Paramedic Act, as the students' understanding of the treatment doubled and approximately 80% of their' understanding improved through VR teaching materials.
While 39% (n=380) of the students had a good understanding of in-hospital team collaboration before taking the VR classes, 80% (n=319) of the students had a good understanding of in-hospital team collaboration after taking the VR classes.
A comparison of the levels of understanding in 6 items rated out of 5 points before and after taking VR training showed that the levels of understanding were all significantly improved after VR training.
OPEcloud VR is a VR clinical training platform that easily turns any case into high-precision VR with the permanent installation of a 360 VR camera and server in the medical facility.

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection

Retrieved on:

Friday, January 22, 2021

Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Health, Syndromes, Drugs, Clinical medicine, Hunter syndrome, Mucopolysaccharidosis, ICV, Heroin, Vestronidase alfa, mucopolysaccharidosis type II, Clinigen K.K., GC Pharma

(Clinigen), headquartered in Tokyo, has received on January 22, 2021, Japan manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for mucopolysaccharidosis type II (Hunter syndrome).

Key Points:

(Clinigen), headquartered in Tokyo, has received on January 22, 2021, Japan manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for mucopolysaccharidosis type II (Hunter syndrome).
An enzyme-replacement therapy drug for intravenous injection is already in use in Japan and other countries as a treatment for systemic symptoms of mucopolysaccharidosis type II.
The approval in Japan is ahead of the world, being the first approval of Hunterase ICV Injection in any country worldwide.
Hunterase ICV Injection 15 mg is also the worlds first and only drug for the treatment of central nervous system symptoms of mucopolysaccharidosis type II.